Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramulus Mori alkaloid (SZ-A) vs empagliflozin in diabetic nephropathy via gut–kidney axis
ChiCTR2500113955Phase 4Not yet recruiting
- Sponsor
- Southwest Medical University
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ramulus mori alkaloids in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (2 arms), sponsored by Southwest Medical University. Primary endpoints: Urine protein content, Reactive oxygen species (ROS) and 3 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
ramulus mori alkaloids
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2500113955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113955.